Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced the initiation of IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor. The company has exercised its option for an exclusive worldwide license from Cancer Research UK and the University of Manchester. IDE161 targets tumors with homologous recombination deficiencies, including those with BRCA1 and BRCA2 mutations. IDEAYA plans to submit an IND application for IDE161 in Q4 2022, following successful preclinical studies. The company holds comprehensive rights to IDE161 under its licensing agreement.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced key corporate updates ahead of the J.P. Morgan 40th Annual Healthcare Conference on January 11, 2022. The company reported a robust balance sheet with approximately $386 million in cash and equivalents, expected to fund operations into 2025. They completed enrollment in the Phase 1 trial for IDE397, targeting FDA amendment in Q1 2022. Additionally, IDEAYA aims to submit IND for a PARG inhibitor by Q4 2022 and expand indications for darovasertib. GSK milestone payments of $70 million could be triggered through upcoming developments.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced on January 5, 2022, the acquisition of its INQUIRE™ Chemical Library, a curated collection of over 200,000 compounds aimed at enhancing the company's synthetic lethality drug discovery platform. This acquisition is expected to improve IDEAYA's hit discovery capabilities across challenging targets such as helicases and endonucleases. The company aims to leverage this proprietary library alongside its existing expertise in drug discovery, aiming for advancements in targeted therapeutics and innovative drug candidates.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) has appointed Frank McCormick, Ph.D., FRS, as the Chair of its Scientific Advisory Board. Dr. McCormick is a renowned expert in cancer biology and has a significant background in drug discovery. IDEAYA is known for its pioneering synthetic lethality approach in oncology, developing targeted therapeutics such as darovasertib and IDE397. Dr. McCormick's leadership is expected to enhance IDEAYA's clinical and preclinical pipeline, driving advancements in precision medicine for cancer treatment.
IDEAYA Biosciences (NASDAQ: IDYA) will participate in several investor conferences throughout January 2022, showcasing its focus on precision medicine in oncology.
The events include the LifeSci Advisors Corporate Access Event on January 6, the J.P. Morgan 40th Annual Healthcare Conference on January 11, and the B. Riley Securities' 2022 Oncology Conference on January 27. CEO Yujiro Hata will present at all conferences, emphasizing IDEAYA's commitment to synthetic lethality and patient-targeted therapies.
IDEAYA Biosciences (Nasdaq:IDYA) announced a clinical update on its Phase 1/2 trial combining darovasertib and crizotinib for metastatic uveal melanoma (MUM) patients. With 22 heavily pre-treated patients enrolled, the interim results show a remarkable 100% Disease Control Rate and a 31% Overall Response Rate. The data suggests potential as a new treatment benchmark in this area with high unmet medical need. IDEAYA is also exploring the combination in other tumor types and expects further clinical data in 2022, aimed at regulatory feedback for potential registration.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in investor conferences in December 2021. Notably, they will host a fireside chat at the Evercore ISI HealthConX Conference on December 2, 2021, at 10:30 am ET, featuring CEO Yujiro Hata. A live audio webcast will be available on their website, with replays accessible for 30 days. IDEAYA focuses on discovering targeted therapeutics using synthetic lethality, enhancing treatment for specific patient populations through molecular diagnostics.
IDEAYA Biosciences (NASDAQ: IDYA) will provide a clinical data update on December 7, 2021, focusing on the ongoing Phase 1/2 trial of darovasertib and crizotinib for metastatic uveal melanoma. The company plans a pre-market press release and will host a conference call at 8:30 a.m. ET. Key discussion points include clinical efficacy data, potential registration-enabling trial designs, and target patient population analysis. This event aims to showcase clinical benchmarks and potential expansion into other cancer types.
IDEAYA Biosciences (Nasdaq: IDYA) reported a business update and Q3 2021 financial results. The company is advancing its Phase 1 MAT2A inhibitor, IDE397, with early clinical data showing tumor shrinkage in patients with MTAP deletion. IDEAYA also selected a lead candidate for its PARG program and is collaborating with GlaxoSmithKline (GSK) on multiple synthetic lethality programs. Financially, IDEAYA reported a net loss of $11.6 million, with cash reserves increasing to $385.8 million, sufficient to fund operations into 2025.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in key investor conferences in November 2021. Events include the Northland Capital Biotech Best Ideas Event on November 17, featuring CEO Yujiro Hata in a CEO Roundtable and a panel discussion on synthetic lethality. Additionally, Hata will present at 1:00 PM ET. The Jefferies London Healthcare Conference follows on November 18, with a fireside chat led by Maury Raycroft. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days.